References
- Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metabol Disposit 31:815–32
- Idris I, Donnelly R. (2009). Sodium–glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metabol 11:79–88
- Isaji M. (2007). Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 8:285–92
- Kowa Pharmaceutical Co., Ltd. (2014). Deberza (tofogliflozin) [package insert]. Available from: http://www.kowa-souyaku.co.jp/upload/item/66/4-pt_167.pdf [Japanese] [last accessed 30 Oct 2014]
- Magen D, Sprecher E, Zelikovic I, Skorecki K. (2005). A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 67:34–41
- Nagata T, Fukazawa M, Honda K, et al. (2013a). Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab 304:E414–23
- Nagata T, Fukuzawa T, Takeda M, et al. (2013b). Tofogliflozin, a novel sodium–glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170:519–31
- Ohtake Y, Sato T, Kobayashi T, et al. (2012). Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 55:7828–40
- SANOFI K. K. (2014). Apleway (tofogliflozin) [package insert]. Available from: http://e-mr.sanofi.co.jp/di/tenpu/apleway.pdf?date=20140523174259 [Japanese]. [last accessed 30 Oct 2014]
- Santer R, Kinner M, Lassen CL, et al. (2003). Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873–82
- Scheen AJ. (2005). Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 28:601–31
- Schwab D, Portron A, Backholer Z, et al. (2013). A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [(14)C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [(13)C]tofogliflozin in humans. Clin Pharmacokinet 52:463–73
- Schwab D, Portron A, Fukushima Y, et al. (2012). Tofogliflozin a selective SGLT2 inhibitor exhibits highly favourable drug properties for use in patients with renal impairment and for combination with other medicines. Abstracts of the 48th EASD Annual Meeting of the European Association for the Study of Diabetes; 2012 Oct 1–5; Berlin, Germany. Diabetologia 55:S316
- Suzuki M, Hiramatsu M, Fukazawa M, et al. (2014). Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans. Diabetes, Obes Metabol 16:622–7
- Suzuki M, Honda K, Fukazawa M, et al. (2012). Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341:692–701
- Vallon V, Platt KA, Cunard R, et al. (2011). SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104–12
- Vallon V, Rose M, Gerasimova M, et al. (2013). Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol – Renal Physiol 304:F156–67
- Washburn WN. (2012). Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents. Expert Opin Therapeut Patents 22:483–94
- Yamaguchi K, Kato M, Suzuki M, et al. (2013). In vitro–in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. J Pharmacol Exp Ther 345:52–61
- Zell M, Husser C, Kuhlmann O, et al. (2013). Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica 44:369–78